<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1006965.ref031">
 <label>31</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Flasche</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Jit</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Rodr√≠guez-Barraquer</surname>
   <given-names>I</given-names>
  </name>, 
  <name>
   <surname>Coudeville</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Recker</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Koelle</surname>
   <given-names>K</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study</article-title>. 
  <source>PLoS medicine</source>. 
  <year>2016</year>;
  <volume>13</volume>: 
  <fpage>e1002181</fpage>
  <comment>doi: 
   <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1002181" xmlns:xlink="http://www.w3.org/1999/xlink">10.1371/journal.pmed.1002181</ext-link>
  </comment>
  <?supplied-pmid 27898668?>
  <pub-id pub-id-type="pmid">27898668</pub-id>
 </mixed-citation>
</ref>
